545410-51-3 Usage
General Description
Ethanone, 1-[2,5-bis(trifluoromethyl)phenyl]-2-(1H-imidazol-1-yl)- is a chemical compound that contains a ketone group attached to a trifluoromethylphenyl group and an imidazole ring. Ethanone, 1-[2,5-bis(trifluoromethyl)phenyl]-2-(1H-imidazol-1-yl)- is notable for its potential biological and pharmacological applications, as imidazole-containing compounds have been found to have diverse activities such as antifungal and antimicrobial properties, as well as potential as enzyme inhibitors. The trifluoromethylphenyl group can enhance the compound's lipophilicity and bioavailability, making it a potentially valuable compound for drug development. Additionally, the presence of the imidazole ring suggests potential interactions with biological targets such as enzymes or receptors, further highlighting the compound's potential as a pharmacologically active substance.
Check Digit Verification of cas no
The CAS Registry Mumber 545410-51-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,4,5,4,1 and 0 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 545410-51:
(8*5)+(7*4)+(6*5)+(5*4)+(4*1)+(3*0)+(2*5)+(1*1)=133
133 % 10 = 3
So 545410-51-3 is a valid CAS Registry Number.
545410-51-3Relevant articles and documents
N-[1-Aryl-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F1F0 ATP hydrolase
Atwal, Karnail S.,Ahmad, Saleem,Ding, Charles Z.,Stein, Philip D.,Lloyd, John,Hamann, Lawrence G.,Green, David W.,Ferrara, Francis N.,Wang, Paulina,Rogers, W. Lynn,Doweyko, Lidia M.,Miller, Arthur V.,Bisaha, Sharon N.,Schmidt, Joan B.,Li, Ling,Yost, Kenneth J.,Lan, Hsi-Jung,Madsen, Cort S.
, p. 1027 - 1030 (2007/10/03)
A series of substituted guanidine derivatives were prepared and evaluated as potent and selective inhibitors of mitochondrial F1F0 ATP hydrolase. The initial thiourethane derived lead molecules possessed intriguing in vitro pharmacological profiles, though contained moieties considered non-drug-like. Analogue synthesis efforts led to compounds with maintained potency and superior physical properties. Small molecules in this series which potently and selectivity inhibit ATP hydrolase and not ATP synthase may have utility as cardioprotective agents.
